

APPLICATION NO.
10/686,943

FIRST NAMED INVENTOR
Andrew McMichael

FILING DATE
October 16, 2003

November 6, 2006

EXAMINER
Louise Humphrey, Ph.D.

CONFIRMATION NO.
4585

GROUP
1648

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

[illegible]

EXAMINER

/Louise Humphrey/

DATE CONSIDERED

03/26/2007

[illegible]

@PFDesktop\::ODMA\MHODMA\HBSR05;iManage;652171;1

PTO-1449 REPRODUCED THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION November 6, 2006 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2907.1000-003		APPLICATION NO. 10/686,943	
	FIRST NAMED INVENTOR Andrew McMichael		FILING DATE October 16, 2003	
	EXAMINER Louise Humphrey, Ph.D.	CONFIRMATION NO. 4585	GROUP 1648	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
L.H.	C1	Afonso, C.L., <i>et al.</i> , "The Genome of Fowlpox Virus," <i>J. Virol.</i> 74(8):3815-3831 (2000).
	C2	Anderson, <i>et al.</i> , "Enhanced CD8 T Cell Response and Protective Efficacy Against Malaria Using Recombinant Fowlpox Virus In Heterologous Prime/Boost Immunisation Regimes," Abstract, <i>Immunology</i> 101(Supplement 1):32 (2000).
	C3	Berkner, K.L., "Development of Adenovirus Vectors for the Expression of Heterologous Genes," <i>BioTechniques</i> 6(7): 616-629 (1988).
	C4	Boulanger, D., <i>et al.</i> , "Morphogenesis and Release of Fowlpox Virus," <i>J. Gen. Virol.</i> 81:675-687 (2000).
	C5	Boulanger, D., <i>et al.</i> , "The 131-Amino-Acid Repeat Region of the Essential 39-Kilodalton Core Protein of Fowlpox Virus FP9, Equivilant to Vaccinia Virus A4L Protein, Is Nonessential and Highly Immunogenic," <i>J. Virol</i> 72(1):170-179 (1998).
	C6	Boursnell, M.E.G., <i>et al.</i> , "A Fowlpox Virus Vaccine Vector with Insertion Sites in the Terminal Repeats: Demonstration of its Efficacy Using the Fusion Gene of Newcastle Disease Virus," <i>Vet. Microbiol.</i> 23:305-316 (1990).
	C7	Boursnell, M.E.G., <i>et al.</i> , "Insertion of the Fusion Gene from Newcastle Disease Virus into a Non-essential Region in the Terminal Repeats of Fowlpox Virus and Demonstration of Protective Immunity Induced by the Recombinant," <i>J. Gen. Virology</i> 71:621-628 (1990).
	C8	Boyle, D.B. and Heine, H.G., "Recombinant Fowlpox Virus Vaccines for Poultry," <i>Immunol. Cell Biol.</i> 71:391-397 (1993).
	C9	Boyle, D.B., <i>et al.</i> , "Comparison of Field and Vaccine Strains of Australian Fowlpox Viruses," <i>Arch. Virol.</i> 142:737-748 (1997).
	C10	Brooks, J.V., <i>et al.</i> , "Boosting Vaccine for Tuberculosis," <i>Infect. Immun.</i> 69(4): 2714-2717 (2001).
	C11	Buge, S.L., <i>et al.</i> , "Factors Associated with Slow Disease Progression in Macaques Immunized with an Adenovirus-Simian Immunodeficiency Virus (SIV) Envelope Priming-gp120 Boosting Regimen and Challenged Vaginally with SIVmac251," <i>J. Virol.</i> 73(9):7430-7440 (1999).
✓	C12	Campbell, J.I.A., <i>et al.</i> , "Tandem Repeated Sequences Within the Terminal Region of the Fowlpox Virus Genome," <i>J. Gen. Virol.</i> 70:145-154 (1989).

EXAMINER /Louise Humphrey/	DATE CONSIDERED 03/26/2007
-------------------------------	-------------------------------

PTO-1449 REPRODUCED THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION November 6, 2006 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2907.1000-003		APPLICATION NO. 10/686,943	
	FIRST NAMED INVENTOR Andrew McMichael		FILING DATE October 16, 2003	
	EXAMINER Louise Humphrey, Ph.D.	CONFIRMATION NO. 4585	GROUP 1648	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
L.H.	C13	Carter, B.J., <i>et al.</i> , "Gene Therapy as Drug Development," <i>Mol. Therapy</i> 1:(3)211-212 (2000).
	C14	Carvalho, L.J.M., <i>et al.</i> , "Malaria Vaccine: Candidate Antigens, Mechanisms, Constraints and Prospects," <i>Scand. J. Immunol.</i> 56:327-343 (2002).
	C15	Conry, R.M., <i>et al.</i> , "Safety and Immunogenicity of a DNA Vaccine Encoding Carcinoembryonic Antigen and Hepatitis B Surface Antigen in Colorectal Carcinoma Patients," <i>Clin. Cancer Res.</i> 8:2782-2787 (2002).
	C16	Coupar, B.E.H., <i>et al.</i> , "Restriction Endonuclease Mapping of the Fowlpox Virus Genome," <i>Virology</i> 179:159-167 (1990).
	C17	Dale, C. J., <i>et al.</i> , "Induction of HIV-1-Specific T-Helper Responses and Type 1 Cytokine Secretion Following Therapeutic Vaccination of Macaques with a Recombinant Fowlpoxvirus Co-expressing Interferon-Gamma," <i>J. Med. Primatol.</i> 29:240-247 (2000).
	C18	Davis, H.L., <i>et al.</i> , "DNA-Mediated Immunization to Hepatitis B Surface Antigen: Longevity of Primary Response and Effect of Boost," <i>Vaccine</i> 14(9):910-915 (1996).
	C19	Denis, O., <i>et al.</i> , "Vaccination with Plasmid DNA Encoding Mycobacterial Antigen 85A Stimulates a CD4+ and CD8+ T-Cell Epitopic Repertoire Broader than that Stimulated by <i>Mycobacterium tuberculosis</i> H37Rv Infection," <i>Infect. Immun.</i> 66(4):1527-1533 (1998)
	C20	E-mail dated January 5, 2006 from American Society for Microbiology re: Date of Disclosure of Buge's Document.
	C21	Grosenbach, D. W., <i>et al.</i> , "Synergy of Vaccine Strategies to Amplify Antigen-specific Immune Responses and Antitumor Effects," <i>Cancer Res</i> 61:4497-4505 (2001).
	C22	Hertig, C., <i>et al.</i> , "Field and Vaccine Strains of Fowlpox Virus Carry Integrated Sequences from the Avian Retrovirus, Reticuloendotheliosis Virus," <i>Virology</i> 35:367-376 (1997).
↓	C23	Holder, A., <i>et al.</i> , "Falciparum Malaria MSP1 Workshop: Progress toward MSP1 Vaccine Development and Testing," <i>Malaria Vaccine Initiative at PATH</i> : 1-30 (2000).

EXAMINER /Louise Humphrey/	DATE CONSIDERED 03/26/2007
-------------------------------	-------------------------------

PTO-1449 REPRODUCED THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION November 6, 2006 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2907.1000-003		APPLICATION NO. 10/686,943	
	FIRST NAMED INVENTOR Andrew McMichael		FILING DATE October 16, 2003	
	EXAMINER Louise Humphrey, Ph.D.	CONFIRMATION NO. 4585	GROUP 1648	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

L.H.	C24	Johnson, R.P., <i>et al.</i> , "Induction of a Major Histocompatibility Complex Class I-Restricted Cytotoxic T-Lymphocyte Response to a Highly Conserved Region of Human Immunodeficiency Virus Type 1 (HIV-1) gp120 in Seronegative Humans Immunized with a Candidate HIV-1 Vaccine," <i>J. Virol.</i> 68(5):3145-3153 (1994).
	C25	Kazanji, M., <i>et al.</i> "Expression and Immunogenicity in Rats of Recombinant Adenovirus 5 DNA Plasmids and Vaccinia Virus Containing the HTLV-I <i>inv</i> Gene," <i>Int. J. Cancer</i> 71:300-307 (1997).
	C26	Kent, S.J., <i>et al.</i> , "A Recombinant Avipoxvirus HIV-1 Vaccine Expressing Interferon-gamma is Safe and Immunogenic in Macaques," <i>Vaccine</i> 18:2250-2256 (1999).
	C27	Kent, S.J., <i>et al.</i> , "Enhanced T-Cell Immunogenicity and Protective Efficacy of a Human Immunodeficiency Virus Type 1 Vaccine Regimen Consisting of Consecutive Priming with DNA and Boosting with Recombinant Fowlpox Virus," <i>J. Virol.</i> 72(12):10180-10188 (1998).
	C28	Kent, S.J., <i>et al.</i> , "Analysis of Cytotoxic T Lymphocyte Responses to SIV Proteins in SIV-Infected Macaques Using Antigen-Specific Stimulation with Recombinant Vaccinia and Fowl Poxviruses," <i>AIDS Res. Hum. Retroviruses</i> 10(5):551-560 (1994).
	C29	Laidlaw, S.M. and Skinner, M.A., "Comparison of the Genome Sequence of FP9, an Attenuated, Tissue Culture-adapted European Strain of <i>Fowlpox virus</i> , with Those of Virulent American and European Viruses," <i>J. Gen. Virol.</i> 85:305-322 (2004).
	C30	Laidlaw, S.M., <i>et al.</i> , "Fowlpox Virus Encodes Nonessential Homologs of Cellular Alpha-SNAP, PC-1, and an Orphan Human Homolog of a Secreted Nematode Protein," <i>J. Virol.</i> 72(8):6742-6751 (1998).
	C31	Mayr, A. and Malicki, K., "Attenuierung von virulentem Hühnerpockenvirus in Zellkulturen und Eigenschaften des attenuierten Virus," <i>Zbl. Vet. Med. B</i> B13, 1-13 (1966). (ENGLISH ABSTRACT)
	C32	Meyer, H., <i>et al.</i> , "Mapping of Deletions in the Genome of the Highly Attenuated Vaccinia Virus MVA and their Influence on Virulence," <i>J. Gen. Virol.</i> 72:1031-1038 (1991).
	C33	Moss, B., "Genetically Engineered Poxviruses for Recombinant Gene Expression, Vaccination, and Safety," <i>Proc. Natl. Acad. Sci. USA</i> 93:11341-11348 (1996).
	C34	Natuk, R.J., <i>et al.</i> , "Immunogenicity of Recombinant Human Adenovirus-Human Immunodeficiency Virus Vaccines in Chimpanzees," <i>Aids Res. Hum. Retroviruses</i> (9):395-404 (1993).

EXAMINER /Louise Humphrey/	DATE CONSIDERED 03/26/2007
-------------------------------	-------------------------------

PTO-1449 REPRODUCED THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION November 6, 2006 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2907.1000-003		APPLICATION NO. 10/686,943	
	FIRST NAMED INVENTOR Andrew McMichael		FILING DATE October 16, 2003	
	EXAMINER Louise Humphrey, Ph.D.	CONFIRMATION NO. 4585	GROUP 1648	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

L.H.	C35	NCBI Accession No. AF198100, "Fowlpox virus, complete genome," [online], March 2000. [retrieved on 2006-09-14] Retrieved from the Internet <URL: http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=7271507 >.
	C36	Niewiesk, S., <i>et al.</i> , "Measles Virus-Induced Immune Suppression in the Cotton Rat (<i>Sigmodon hispidus</i>) Model Depends on Viral Glycoproteins," <i>J. Virol.</i> 71(10):7214-7219 (1997).
	C37	Notice of Opposition to a European Patent. Patent No.: EP 1 214 416. Opponent: Transgene S.A. (English translation attached.)
	C38	Notice of Opposition to a European Patent. Patent No.: EP 1 214 416 B1. Opponent: Merck & Co., Inc.
	C39	Notice of Opposition to a European Patent. Patent No.: EP 1 214 416 B1. Opponent: Crucell Holland B.V.
	C40	Paoletti, E., "Applications of Pox Virus Vectors to Vaccination: An Update," <i>Proc. Natl. Acad. Sci. USA</i> 93:11349-11353 (1996).
	C41	Pollitt, E., <i>et al.</i> , "Nucleotide Sequence of the 4.3 kbp BamHI-N Fragment of Fowlpox Virus FP9," <i>Virus Genes</i> 17(1):5-9 (1998).
	C42	Qingzhong, Y., <i>et al.</i> , "Protection Against Turkey Rhinotracheitis Pneumovirus (TRTV) Induced by a Fowlpox Virus Recombinant Expressing the TRTV Fusion Glycoprotein (F)," <i>Vaccine</i> 12(6):569-573 (1994).
	C43	Ramarathinam, L., <i>et al.</i> , "Multiple Lineages of Tumors Express a Common Tumor Antigen, P1A, but they are not Cross-Protected," <i>J. Immunol.</i> 155: 5323-5329 (1995).
	C44	Robert-Guroff, M., <i>et al.</i> , "Vaccine Protection Against a Heterologous, Non-Syncytium-Inducing, Primary Human Immunodeficiency Virus," <i>J. Virol.</i> 72(12):10275-10280 (1998).
	C45	Robinson, H.L., <i>et al.</i> , "Neutralizing Antibody-independent Containment of Immunodeficiency Virus Challenges by DNA Priming and Recombinant Pox Virus Booster Immunizations," <i>Nature Med.</i> 5(5):526-534 (1999).
↓	C46	Rodrigues, E.G., <i>et al.</i> , "Efficient Induction of Protective Anti-Malaria Immunity By Recombinant Adenovirus," <i>Vaccine</i> 16(19):1812-1817, (1998).

EXAMINER /Louise Humphrey/	DATE CONSIDERED 03/26/2007
-----------------------------------	-----------------------------------

PTO-1449 REPRODUCED THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION November 6, 2006 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2907.1000-003		APPLICATION NO. 10/686,943	
	FIRST NAMED INVENTOR Andrew McMichael		FILING DATE October 16, 2003	
	EXAMINER Louise Humphrey, Ph.D.	CONFIRMATION NO. 4585	GROUP 1648	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
L.H.	C47	Rothel, J.S., <i>et al.</i> , "Sequential Nucleic Acid and Recombinant Adenovirus Vaccination Induces Host-protective Immune Responses Against <i>Taenia ovis</i> infection in Sheep," <i>Parasite Immunology</i> 19:221-227 (1997).
	C48	Shah, K.V. and Howley, P.M., "Papillomaviruses." In <i>Fields Virology</i> , B.N. Fields, <i>et al.</i> , eds. (PA: Lippincott-Raven Publishers) pp. 2077-2109 (1996).
	C49	Shaw, I. and Davison, T.F., "Protection From IBDV-Induced Bursal Damage By A Recombinant Fowlpox Vaccine, fplBD1, Is Dependent ON the Titre of Challenge Virus and Chicken Genotype," <i>Vaccine</i> 18:3230-3241 (2000).
	C50	Skinner, M.A., <i>et al.</i> , "Fowlpox Virus as a Recombinant Vaccine Vector for use in Mammals and Poultry," <i>Expert Rev. Vaccines</i> 4(1):63-76 (2005).
	C51	Somogyi, P., <i>et al.</i> , "Fowlpox Virus Host Range Restriction: Gene Expression, DNA Replication, and Morphogenesis in Nonpermissive Mammalian Cells," <i>Virology</i> 197:439-444 (1993).
	C52	Sutter, G. and Moss, B., "Nonreplicating Vaccinia Vector Efficiently Expresses Recombinant Genes," <i>Proc. Natl. Acad. Sci. USA</i> , 89:10847-10851 (1992).
	C53	Tanghe, A., <i>et al.</i> , "Improved Immunogenicity and Protective Efficacy of a Tuberculosis DNA Vaccine Encoding Ag85 by Protein Boosting," <i>Infect. Immun.</i> 69(5):3041-3047 (2001).
	C54	Taylor, J. and Paoletti, E., "Fowlpox Virus As A Vector in Non-Avian Species," <i>Vaccine</i> 6:466-468 (1988).
	C55	Taylor, J., <i>et al.</i> , "Protective Immunity Against Avian Influenza Induced by a Fowlpox Virus Recombinant," <i>Vaccine</i> 6:504-508 (1988).
	C56	Taylor, J., <i>et al.</i> , "Recombinant Fowlpox Virus Inducing Protective Immunity in Non-Avian Species," <i>Vaccine</i> 6(6):497-503 (1988).
↓	C57	Thomson, S.A., <i>et al.</i> , "Delivery of Multiple CD8 Cytotoxic T Cell Epitopes by DNA Vaccination," <i>J. Immunol.</i> 160:1717-1723 (1998).

EXAMINER /Louise Humphrey/	DATE CONSIDERED 03/26/2007
-------------------------------	-------------------------------

PTO-1449 REPRODUCED THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION November 6, 2006 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2907.1000-003		APPLICATION NO. 10/686,943	
	FIRST NAMED INVENTOR Andrew McMichael		FILING DATE October 16, 2003	
	EXAMINER Louise Humphrey, Ph.D.	CONFIRMATION NO. 4585	GROUP 1648	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

L.H.	C58	Timofeev, A.V., <i>et al.</i> , "Immunological Basis for Protection in a Murine Model of Tick-Borne Encephalitis by a Recombinant Adenovirus Carrying the Gene Encoding the NS1 Non-Structural Protein," <i>J. Gen. Virol.</i> 79:689-695 (1998).
	C59	Timofeyev, A.V., <i>et al.</i> , "Recombinant Adenovirus Expressing the NS1 Nonstructural Protein of Tick-Borne Encephalitis Virus: Characteristics of Immunological Basis of Antiviral Effect," <i>Vopr. Virusol.</i> 42:219-222 (1997). (English Abstract attached.)
	C60	Tsukamoto, K., <i>et al.</i> , "Dual-Viral Vector Approach Induced Strong and Long-Lasting Protective Immunity against Very Virulent Infectious Bursal Disease Virus," <i>Virology</i> 269(2):257-267 (2000).
	C61	Warnier, G., <i>et al.</i> , "Induction of a Cytolytic T-cell Response in Mice with a Recombinant Adenovirus Coding for Tumor Antigen P815A" <i>Int. J. Cancer</i> 67(2):303-310 (1996). (Abstract only).
↓	C62	Xiang, Z.Q., <i>et al.</i> , "Induction of Genital Immunity by DNA Priming and Intranasal Booster Immunization with a Replication-Defective Adenoviral Recombinant," <i>J. Immunol.</i> 162: 6716-6723 (1999).

EXAMINER /Louise Humphrey/	DATE CONSIDERED 03/26/2007
-------------------------------	-------------------------------